http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
개별검색 DB통합검색이 안되는 DB는 DB아이콘을 클릭하여 이용하실 수 있습니다.
통계정보 및 조사
예술 / 패션
<해외전자자료 이용권한 안내>
- 이용 대상 : RISS의 모든 해외전자자료는 교수, 강사, 대학(원)생, 연구원, 대학직원에 한하여(로그인 필수) 이용 가능
- 구독대학 소속 이용자: RISS 해외전자자료 통합검색 및 등록된 대학IP 대역 내에서 24시간 무료 이용
- 미구독대학 소속 이용자: RISS 해외전자자료 통합검색을 통한 오후 4시~익일 오전 9시 무료 이용
※ 단, EBSCO ASC/BSC(오후 5시~익일 오전 9시 무료 이용)
This study was conducted to identify the knowledge of HPV and HPV vaccines and the acceptance of cancer preventive vaccine targeting adult women. The convenience sampling was conducted on subjects of 271 adult women who have visited Gynecologic Clinics residing in the B-city. For data analysis, it conducted the analysis of mean and standard deviation, t-test, ANOVA, and Pearson's Correlation Coefficient. The research results demonstrate that the knowledge about HPV vaccine was higher in less than 40's in their age, subjects over college-graduates, single status in marriage condition, and subjects who have jobs, but the knowledge appeared to be very low with mean score, 5.34 (range 0∼22). In terms of the performance of cancer prevention, subjects of college graduates, those who have religion and were in higher economic level, those who are married, have no job, have a sex-partner and sexually transmitted diseases experience specially made an effort to prevent cancer. Of the subjects, 66.7% responded that they had a will to receive HPV vaccination and 86% subjects wanted to make their children vaccinate. In addition, there was no correlation found between the knowledge of HPV vaccine and the cancer- preventive performance.
Purpose To estimate the current cancer burden in Korea, cancer incidence and mortality rates were projected for the year 2013. Materials and Methods Cancer incidence data from 1999 to 2010 were obtained from the Korea National Cancer Incidence Database, and cancer mortality data from 1993 to 2011 were obtained from Statistics Korea. Cancer incidence in 2013 was projected by fitting a linear regression model to observed age-specific cancer incidence rates against observed years, then multiplying the projected age-specific rates by the age-specific population. For cancer mortality, a similar procedure was used, except that a Joinpoint regression model was used to determine at which year the linear trend changed significantly. Results In total, 247,732 new cancer cases and 74,179 cancer deaths are projected to occur in Korea in 2013. For all sites combined, the crude incidence rates are projected to be 489.8 and 492.2, and the age-standardized incidences to be 350.4 and 318.4per 100,000 for males and females, respectively. Conclusion Cancer has become an important public health concern in Korea, and as the Korean population ages, the cancer burden will continue to increase.
Purpose Although the cancer stage at diagnosis is the most important prognostic factor for patients’ survival, there are few population-based estimates of stage-specific survival outcome, especially in Asian countries. Our study aims to estimate stage-specific survival for Korean patients. Materials and Methods We analyzed the Korea National Cancer Incidence Database data on 626,506 adult patients aged ≥ 20 years, who were diagnosed between 2006 and 2010 with stomach,colorectal, liver, lung, breast, cervix, prostate, and thyroid cancers. Patients were followed up to December 2011, and the 5-year relative survival rates (RSRs) were calculated for gender and age group by Surveillance, Epidemiology, and End Results (SEER) stage at diagnosis. Results The 5-year RSRs for all localized-stage cancers, except for lung and liver, exceeded 90% with that for thyroid cancer being the highest at 100.4%. These values for distant stage liver, lung, and stomach cancers were very dismal at 2.5%, 4.8%, and 5.5%,respectively, while it was 69.1% for thyroid cancer, and was in the range of 18.3-36.4% for colorectal, cervix, breast and prostate cancers. Overall, the 5-year RSRs for all cancer types decreased with aging across all the disease stages with exception of prostate cancer, which suggests biologic difference in these cancer types in a young age group. When compared with US SEER data, Korean patients had better stagespecific survival rates for stomach, colorectal, liver, and cervical cancers. Conclusion Korean cancer patients showed relatively favorable stage distribution and 5-year RSRs, which suggests potential contribution of the national cancer screening program.
Purpose This study was designed to investigate the long-term oncologic outcomes for locally advanced rectal cancer patients after treatment with preoperative concurrent chemoradiotherapy followed by total mesorectal excision, and to identify prognostic factors that affect survival and pathologic response. Materials and Methods From June 1996 to June 2009, 135 patients with locally advanced rectal cancer were treated with preoperative concurrent chemoradiotherapy followed by total mesorectal excision at Kyung Hee University Hospital. Patient data was retrospectively collected and analyzed in order to determine the treatment outcomes and identify prognostic factors for survival. Results The median follow-up time was 50 months (range, 4.5 to 157.8 months). After preoperative chemoradiotherapy, sphincter preservation surgery was accomplished in 67.4% of whole patients. A complete pathologic response was achieved in 16% of patients. The estimated 5- and 8-year overall survival, loco-regional recurrence-free survival, and distant metastasis-free survival rate for all patients was 82.7% and 75.7%, 76.8% and 71.9%, 67.9% and 63.3%, respectively. The estimated 5- and 8-year overall survival, loco-regional recurrence-free survival, and distant metastasis-free survival rate for pathologic complete responders was 100% and 100%, 100% and 88.9%,95.5% and 95.5%, respectively. In the multivariate analysis, pathologic complete response was significantly associated with overall survival. The predictive factor for pathologic complete response was pretreatment clinical stage. Conclusion Preoperative chemoradiotherapy for locally advanced rectal cancer resulted in a high rate of overall survival, sphincter preservation, down-staging, and pathologic complete response. The patients achieving pathologic complete response had very favorable outcomes. Pathologic complete response was a significant prognostic factor for overall survival and the significant predictive factor for a pathologic complete response was pretreatment clinical stage.
The MCM protein family has six highly conserved subunits, MCM2 to 7, and is essential for initiation and elongation of DNA replication in all eukaryotes. Deregulation of the MCM function and expression resulted in cells undergoing tumorigenesis. Therefore, these proteins are potential diagnostic markers for cancer and promising targets for anticancer drug development. On the other hand, recently marine organisms are regarded as attractive sources of novel anticancer compounds due to their tremendous biodiversity. In this study, we screened several seaweed for down-regulatory compound of MCM and selected Corallina pilulifera as candidate. Ethanolic extract of Corallina pilulifera (EECP) reduced MCM expression in a dose-dependent manner(0-200μg/ml). EECP showed cytotoxic and antiproliferative activity against six human cancer cells tested such as HeLa, HT29, T24, HepG2, A549 and Jurkat E6-1. A 30% of tumor mass volume reduction was observed in vivo experiment using mouse bearing Sarcoma 180 cells after treatment of EECP for 14 days, and antitumor efficacy was 72.1%. Oligonucleotide microarray analysis identified 69 up-regulated genes and 79 down-regulated genes in HeLa cells after EECP treatment. The deregulated genes were involved in various biological process including cell cycle regulation and cell proliferation, signal transduction, apoptosis, and predominantly down-regulated genes were mainly associated with cell cycle. (Cancer Prev Res 11, 346-353, 2006)
Purpose: We investigated the efficacy and safety of a combination of oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) as first-line palliative chemotherapy for elderly patients with metastatic or recurrent gastric cancer.Materials and Methods: The study patients were chemotherapy-naïve patients (〉 65 years old) with histologically confirmed, metastatic or recurrent gastric cancer. Chemotherapy consisted of oxaliplatin 100 mg/m2 and FA 100 mg/m2 (2-hour infusion), and then 5-FU 2400 mg/m2 (46-hour continuous infusion) every 2 weeks.Results: A total of 37 patients were studied between April 2004 and October 2006. Of the 34 evaluable patients, none achieved a complete response (CR) and 14 achieved a partial response (PR), resulting in an overall response rate of 41.2%. The median time to progression (TTP) was 5.7 months (95% CI: 4.2∼6.3 months) and the median overall survival (OS) was 9.8 months (95% CI: 4.4∼12.0 months). The main hematologic toxicities were anemia and neutropenia, which were observed in 56.7% and 32.4% of the patients, respectively. Grade 3/4 neutropenia was observed in 8.1% of the patients. None of the patients experienced febrile neutropenia. Peripheral neuropathy occurred in 35.1% of the patients and all were grade 1/2.Conclusion: This oxaliplatin/5-FU/FA regimen showed good efficacy and an acceptable toxicity profile in elderly patients with metastatic or recurrent gastric cancer. (Cancer Res Treat. 2007;39:99-103)
Purpose This article gives an overview of nationwide cancer statistics, including incidence,mortality, survival and prevalence, and their trends in Korea based on 2010 cancer incidence data. Materials and Methods Incidence data from 1993 to 2010 were obtained from the Korea National Cancer Incidence Database, and vital status was followed until 31 December 2011. Mortality data from 1983 to 2010 were obtained from Statistics Korea. Crude and agestandardized rates for incidence, mortality, prevalence, and relative survival were calculated. Results In total, 202,053 cancer cases and 72,046 cancer deaths occurred during 2010,and 960,654 prevalent cancer cases were identified in Korea as of 1 January 2011. The incidence of all cancers combined showed an annual increase of 3.3% from 1999to 2010. The incidences of liver and cervical cancers have decreased while those of thyroid, breast, prostate and colorectal cancers have increased. Notably, thyroid cancer,which is the most common cancer in Korea, increased by 24.2% per year rapidly in both sexes. The mortality of all cancers combined showed a decrease by 2.7%annually from 2002 to 2010. Five-year relative survival rates of patients who were diagnosed with cancer from 2006 to 2011 had improved by 22.9% compared with those from 1993 to1995. Conclusion While the overall cancer incidence in Korea has increased rapidly, age-standardized cancer mortality rates have declined since 2002 and survival has improved.
Purpose This study aimed to report on cancer incidence and mortality for the year 2017 in Korea in order to estimate the nation’s current cancer burden. Materials and Methods Cancer incidence data from 1999 to 2014 were obtained from the Korea National Cancer Incidence Database, and cancer mortality data from 1993 to 2015 were acquired from Statistics Korea. Cancer incidence and mortality were projected by fitting a linear regression model to observe age-specific cancer rates against observed years, and then multiplying the projected age-specific rates by the age-specific population. The Joinpoint regression model was used to determine at which year the linear trend changed significantly; we only used data of the latest trend. Results A total of 221,143 new cancer cases and 80,268 cancer deaths are expected to occur in Korea in 2017. The most common cancer sites are the colorectum, stomach, lung, thyroid, and breast. These five cancers represent half of the overall burden of cancer in Korea. For mortality, the most common sites are the lung, liver, colorectal, stomach, and pancreas. Conclusion The incidence rate of all cancers in Korea appears to have decreased mainly because of a decrease in thyroid cancer. These up-to-date estimates of the cancer burden in Korea could be an important resource for planning and evaluation of cancer-control programs.
Purpose The pattern of double primary cancer after treatment for breast cancer is important forpatient survival. Materials and MethodsWe analyzed 108 cases of metachronous double primary cancer in breast cancer patientstreated from 1999 to 2012. ResultsMetachronous double primary cancers occurred in 108 of 2,657 patients (4.1%) with breastcancer. The median time to the occurrence of second cancer after diagnosis of the first was58.4±41.2 months (range, 6.9 to 180.2 months). The most common cancer was thyroidcancer, which occurred in 45 patients (41.7%). This was followed by gastric cancer in 16patients (14.8%), endometrial cancer in 10 patients (9.3%), and cervical cancer in sevenpatients (6.5%). The relative risk showed a significant increase in endometrial (4.78; 95%confidence interval [CI], 1.66 to 13.79), gastric (2.61; 95% CI, 1.68 to 4.06), and thyroidcancer (1.95; 95% CI, 1.37 to 2.79). At 5 years after diagnosis of breast cancer, secondarycancer occurred in 48 patients (44.4%), with 50.0% of the endometrial, 56.3% of the stomach,and 37.8% of the thyroid cancer cases being diagnosed after 5 years. Median survivalafter diagnosis of the second cancer was 123.9±11.2 months. The prognosis was mainlyinfluenced by the anatomic site. ConclusionThe incidence of endometrial, stomach, and thyroid cancer increased significantly aftertreatment with primary breast cancer, and survival was dependent on early detection andthe type of second primary cancer. A prolonged follow-up examination for metachronousdouble primary cancer is needed to provide early detection and improve survival time inpatients with breast cancer.